stockrowLakefront Biotherapeutics - Sponsored ADR
LKFT Healthcare Biotechnology
Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- +198.9%
- Free cash flow
- +18.2%
Quarter to June 2026, against a year earlier
Follow LKFT
Alert me
Lakefront Biotherapeutics - Sponsored ADR (LKFT) EV/EBITDA
As of 5 November 2026, Lakefront Biotherapeutics - Sponsored ADR (LKFT) trades at a EV/EBITDA of 0.9×. Over the past ten years it has ranged from 0.0× (February 2021) to 95.4× (March 2017); the current reading is higher than 33% of that period. That is above the Biotechnology industry median of 0.7× and below the Healthcare sector median of 8.4×.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 3.7× | (49.44%) |
| FY2024 | 7.3× | 24.80% |
| FY2023 | 5.9× | 2.24% |
| FY2022 | 5.7× | (49.33%) |
| FY2021 | 11.3× | — |
| FY2020 | 0.0× | — |
| FY2019 | 12.9× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 62.9× | 135.90% |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Mar 2026 | 3.6× | (25.18%) |
| Mar 2025 | 4.8× | (28.70%) |
| Mar 2024 | 6.8× | (12.51%) |
| Sep 2023 | 7.8× | 22.97% |
| 28 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| PVLA Palvella Therapeutics, Inc. compare | n/m |
| BHVN Biohaven Ltd. compare | n/m |
| ZYME Zymeworks Inc. compare | n/m |
| SEPN Septerna, Inc. compare | n/m |
| VERA Vera Therapeutics, Inc. compare | n/m |
| IMNM Immunome, Inc. compare | n/m |
| LKFT Lakefront Biotherapeutics - Sponsored ADR | 0.9× |
| AUPH Aurinia Pharmaceuticals Inc compare | 10.5× |
| VCEL Vericel Corporation compare | 79.1× |
| Biotechnology industry median | 0.7× |
| Healthcare sector median | 8.4× |
| Market median | 10.9× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on LKFT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement